Table 1.
Completion of follow-up status by completion of treatment in the North American and non-North American regions combined*
| Did not complete treatment (n = 1601) | Completed treatment (n = 5460) | |||
|---|---|---|---|---|
| Did not complete follow-up (n = 419) | Completed follow-up (n = 1182) | Did not complete follow-up (n = 422) | Completed follow-up (n = 5038) | |
| Regimen | n (%) | n (%) | n (%) | n (%) |
| 3HP-DOT (n = 3643)† | 155 (37.0) | 485 (41.0) | 238 (56.4) | 2765 (54.9) |
| 9H-SAT (n = 3418)† | 264 (63.0) | 697 (59.0) | 184 (43.6) | 2273 (45.1) |
| Total (n = 7061) | 419 (26.2)‡ | 1182 (73.8)‡ | 422 (7.7)§ | 5038 (92.3)§ |
Proportion of non-completion of follow-up between those who did not complete treatment (419/1601, 26.2%)vs. those who completed treatment (422/5460, 7.7%) was statistically significant (P < 0.001).
3HP-DOT = 3 months of directly observed once-weekly RPT (maximum dose, 900 mg) plus INH (maximum dose, 900 mg); 9H-SAT = 9 months of daily selfadministered INH (maximum dose, 300 mg). Participants had the opportunity to continue study follow-up after completion or discontinuation of treatment.
The denominator for the percentage is all participants who did not complete treatment (n = 1601).
The denominator for the percentage is all participants who completed treatment (n =5460).
H, INH = isoniazid; P, RPT = rifapentine; DOT = directly observed therapy; SAT = self-administered therapy.